Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases

Expert Review of Dermatology

Volumn 8, Issue 5, 2013, Pages 479-487

  Puzanov, Igor ^a   Wolchok, Jedd D ^b   Ascierto, Paolo A ^c   Hamid, Omid ^d   Margolin, Kim ^e  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Angeles Clinic and Research Institute   (United States)

^e SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

brain metastases; melanoma

Indexed keywords

B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; GLYCOPROTEIN GP 100; IPILIMUMAB; PLACEBO; TEMOZOLOMIDE; THALIDOMIDE; VEMURAFENIB;

ADVERSE OUTCOME; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; BRAF GENE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; COLITIS; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOPHYSITIS; LIVER DISEASE; LIVER TOXICITY; METASTATIC MELANOMA; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SEIZURE; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; TUMOR VOLUME; WHOLE BODY RADIATION;

EID: 84886610123     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.2013.835922     Document Type: Review

References (60)

1. Miller AJ, Mihm MC. Melanoma. N. Engl. J. Med. 355(1), 51-65 (2006
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 22(14), 2865-2872 (2004
3. Shapiro DG, Samlowski WE. Management of melanoma brain metastases in the era of targeted therapy. J. Skin Cancer 2011, 845863 (2011
4. Nieder C, Adam M, Astner ST. Disease presentation and outcome in young patients
5. Salvati M, Cervoni L, Caruso R, Gagliardi FM. Solitary cerebral metastasis from melanoma: Value of the en block resection. Clin. Neurol. Neurosurg. 98(1), 12-14 (1996
6. Goulart CR, Mattei TA, Ramina R. Cerebral melanoma metastases: A critical review on diagnostic methods and therapeutic options. ISRN Surg. 2011, 276908 (2011
7. Korn EL, Liu PY, Lee SJ et al. Meta-Analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26(4), 527-534 (2008
8. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88(1), 11-20 (1998
9. Majer M, Jensen RL, Shrieve DC et al. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 110(6), 1329-1337 (2007
10. McWilliams RR, Rao RD, Buckner JC, Link MJ, Markovic S, Brown PD. Melanoma-induced brain metastases. Expert Rev. Anticancer Ther. 8(5), 743-755 (2008
11. Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 117(2), 227-233 (2012
12. Fife KM, Colman MH, Stevens GN et al. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 22(7), 1293-1300 (2004
13. Hanson PW, Elaimy AL, Lamoreaux WT et al. A concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases. World J. Surg. Oncol. 10, 176 (2012
14. Hofmann MA, Hauschild A, Mohr P et al. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patients choice: A multicentre Dermatologic Cooperative Oncology Group trial. Melanoma Res. 21(6), 516-523 (2011
15. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J. Clin. Oncol. 22(6), 1118-1125 (2004
16. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: A systematic review. Oncologist 12(9), 1114-1123 (2007
17. Hwu WJ, Lis E, Menell JH et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: A phase II study. Cancer 103(12), 2590-2597 (2005
18. Agarwala SS, Kirkwood JM, Gore M et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J. Clin. Oncol. 22(11), 2101-2107 (2004
19. Paul MJ, Summers Y, Calvert AH et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 12(2), 175-178 (2002
20. Margolin K, Atkins B, Thompson A et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 128(4), 214-218 (2002
21. Hofmann M, Kiecker F, Wurm R et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J. Neurooncol. 76(1), 59-64 (2006
22. Atkins MB, Sosman JA, Agarwala S et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: A phase II Cytokine Working Group study. Cancer 113(8), 2139-2145 (2008
23. Hoos A, Ibrahim R, Korman A et al. Development of ipilimumab: Contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 37(5), 533-546 (2010
24. Hodi FS, ODay SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
25. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011
26. Lebbé; C, McDermott DF, Robert C et al. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: Subgroup analyses from a phase III trial [abstract]. Ann. Oncol. 21(Suppl. 8), viii401 (2010
27. Heller KN, Pavlick AC, Hodi FS et al. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases [abstract]. J. Clin. Oncol. 29(15 Suppl.), 8581 (2011
28. Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol. 13(5), 459-465 (2012).
29. Di Giacomo AM, Ascierto PA, Pilla L et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): An open-label, single-Arm phase 2 trial. Lancet Oncol. 13(9), 879-886 (2012
30. Wolchok JD, Hoos A, ODay S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009
31. Hodi FS, Oble DA, Drappatz J et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat. Clin. Pract. Oncol. 5(9), 557-561 (2008
32. Schartz NE, Farges C, Madelaine I et al. Compete regression of a previously untreated melanoma brain metastasis with melanoma. Melanoma Res. 20(3), 247-250 (2010
33. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002
34. Chapman PB, Hauschild A, Robert C et al; and BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V200E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011
35. Colombino M, Capone M, Lissia A et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30(20), 2522-2529 (2012
36. Capper D, Berghoff AS, Magerle M et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta. Neuropathol. 123(2), 223-233 (2012
37. Jakob JA, Bassett RL, Ng CS et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16), 4014-4023 (2011
38. Kumar R, Angelini S, Czene K et al. BRAF mutations in metastatic melanoma: A possible association with clinical outcome. Clin. Cancer Res. 9(9), 3362-3368 (2003
39. Long GV, Menzies AM, Nagrial AM et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29(10), 1239-1246 (2011
40. Chapman PB, Hauschild A, Robert C et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma [abstract]. J. Clin. Oncol. 30(15 Suppl.) 8502 (2012
41. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012 366(8), 707-714 (2012
42. Trefzer U, Minor D, Ribas A et al BREAK-2: A phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma [abstract]. Pigment Cell Res. 24, 1020 (2011
43. Dummer R, Rinderknecht J, Goldinger SM et al. An open-label pilot study of vermurafenib in previously treated metastatic melanoma patients with brain metastases [abstract]. J. Clin. Oncol. 29(15 Suppl.), 8548 (2011
44. Kefford R, Arkenau H, Brown MP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract]. J. Clin. Oncol. 28(15 Suppl.), 8503 (2010
45. Long GV, Kefford RF, Carr PJA et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: Evidence of activity in melanoma brain metastases (mets). Presented at: 35th European Society for Medical Oncology Congress. Milan, Italy, 8-12 October 2010
46. Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379(9829), 1893-1901 (2012
47. Kirkwood JM, Long GV, Trefzer U et al. BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) [abstract]. J. Clin. Oncol. 30(15 Suppl.), 8501 (2012
48. Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol. 13(11), 1087-1095 (2012
49. Hauschild A, Grob JJ, Demidov LV et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma [abstract]. J. Clin. Oncol. 30(15 Suppl.), LBA8500 (2012
50. Dummer R, Goldinger SM, Turtschi CP et al. Open-label pilot study of vemurafenib in previously treated metastatic melanoma (mM) patients (pts) with symptomatic brain metastases (BM). Presented at: 37th European Society for Medical Oncology Congress. Vienna, Austria, 28 September-2 October 2012
51. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N. Engl. J. Med. 365(25), 2439-2441 (2011
52. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: Vemurafenib (PLX4032). J. Pharmacol. Exp. Ther. 342(1), 33-40 (2012
53. Mitchell MS. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J. Clin. Oncol. 7(11), 1701-1709 (1989
54. Ma MW, Qian M, Lackaye DJ et al. Challenging the current paradigm of melanoma progression: Brain metastasis as isolated first visceral site. Neuro. Oncol. 14(7), 849-858 (2012
55. Simeone E, De Maio E, Sandomenico F et al. Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): A case report. J. Med. Case Rep. 6(1), 131 (2012
56. Luke JJ, Hodi FS. A new class of treatment for metastatic melanoma. Clin. Cancer Res. 18(1), 9-14 (2012
57. Anker CJ, Ribas A, Grossmann AH et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J. Clin. Oncol. 31(17), e283-287 (2013
58. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
59. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012
60. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013